Stock Watch: Why Have Biotech Acquisitions Paused?

Pharma’s Appetite For Biotech Acquisitions Has Declined In 2021

 
• By Andy Smith

The subdued number of acquisitions of biotech by big pharma has more than one cause. The structural improvement of the process of drug discovery and development at big pharma is the main one.

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

More from Deals

More from Business